Table 3.
Characteristics, treatment and outcome in patients with mIDH1 glioblastoma
| Case No. | Diagnosis | MGMT status | Initial KPS | Age | Sex | Diagnosis for LrGG | EOR for LrGG | RT for LrGG (Gy) | Chemotherapy for LrGG | LrGG- PFS (m) | EOR for GBM | RT for GBM (Gy) | Chemotherapy for GBM | GBM PFS (m) | Treatment at the time of second progression | Rec-pGBM-OS/ sGBM- OS (m) | LrGG-OS/ pGBM-OS (m) | GBM-OS(m) | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | pGBM | Met | 20 | 51 | M | G | 60 | TMZ | 12.9 | – | – | 12.9 | 12.9 | Censored | |||||
| 2 | pGBM | Met | 40 | 38 | F | G | 60 | TMZ | 5.8 | TMZ | 3.8 | 9.5 | 9.5 | Dead | |||||
| 3 | pGBM | Met | 70 | 31 | F | N | 60 | TMZ | 25.7 | no pro. | – | 25.7 | 25.7 | Alive | |||||
| 4 | pGBM | Met | 70 | 51 | M | N | 60 | T + BEV | 13.4 | TMZ, ICE | 5.5 | 18.8 | 18.8 | Dead | |||||
| 5 | pGBM | Met | 80 | 31 | F | N | 60 | TMZ | 6.9 | A | 15 | 27.5 | 27.5 | Alive | |||||
| 6 | pGBM | Met | 90 | 51 | F | N | 60 | TMZ | 28.3 | no pro. | – | 28.3 | 28.3 | Alive | |||||
| 7 | pGBM | Met | 100 | 25 | F | G | 60 | TMZ | 29.9 | no pro. | – | 29.9 | 29.9 | Alive | |||||
| 8 | pGBM | Met | 100 | 49 | F | G | 60 | TMZ | 69.4 | TMZ, BEV, CK | 13.5 | 82.9 | 82.9 | Dead | |||||
| 9 | pGBM | UM | 10 | 34 | M | N | – | – | 0.5 | – | – | 0.5 | 0.5 | Dead | |||||
| 10 | pGBM | UM | 60 | 65 | F | G | 60 | TMZ | 10.5 | – | – | 10.5 | 10.5 | Dead | |||||
| 11 | pGBM | UM | 90 | 42 | F | G | 60 | TMZ | 13.3 | A + BEV, CK, ITK | 23.2 | 36.5 | 36.5 | Dead | |||||
| 12 | sGBM | Met | 30 | 65 | F | GC | N | - | PAV | 46.1 | N | – | TMZ | 2.4 | – | 2.4 | 48.5 | 2.4 | Dead |
| 13 | sGBM | Met | 70 | 28 | F | GC | N | 50 | TMZ | 52.1 | G | – | CE | 9.2 | CE, BEV | 9.2 | 60.3 | 9.2 | Dead |
| 14 | sGBM | Met | 70 | 52 | M | DA | N | 56 | – | 75.0 | N | – | T + BEV | 8.6 | SRT, BEV | 15.9 | 90.9 | 15.9 | Dead |
| 15 | sGBM | Met | 90 | 23 | M | DA | N | – | – | 12.9 | N | 60 | PAV | 2 | PAV, TMZ | 10.1 | 22.9 | 10.1 | Dead |
| 16 | sGBM | Met | 90 | 35 | F | AA | N | 60 | AE | 48.4 | U | – | TMZ | 8.1 | TMZ, CE | 11.9 | 60.4 | 11.9 | Dead |
| 17 | sGBM | Met | 90 | 38 | F | DA | N | 54 | – | 34.2 | N | – | TMZ | 1.4 | TMZ, ICE | 7.1 | 41.4 | 7.1 | Dead |
| 18 | sGBM | UM | 70 | 34 | F | DA | G | 54 | – | 41.2 | N | – | TMZ | 4.3 | – | 6.3 | 47.6 | 6.3 | Dead |
| 19 | sGBM | UM | 70 | 42 | M | DA | N | 60 | A | 65.5 | N | – | TMZ | 7.3 | BEV, ICE, A | 19.4 | 84.9 | 19.4 | Dead |
pGBM, primary glioblastoma; sGBM, secondary glioblastoma; M, male; F, female; AA, anaplastic astrocytoma; DA, diffuse astrocytoma; GC, gliomatosis cerebri; G, gross total removal; N, non-gross total removal; ND, not known dose; MGMT: O6-methylguanine-DNA methyltransferase, Gy, grey; A, ACNU(nimustine); PAV, procarbazine, ACNU and vincristine; AE, ACNU and etoposide; LrGG-PFS, lower grade glioma-progression-free survival; T + BEV, temozolomide and bevacizumab; CE, carboplatin and etoposide; CK, cyberknife; ITK, personalized peptide vaccine; ICE, low dose ifosfamide, carboplatin and etoposide; rec., recurrence.